Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
Randomized phase 3 trial evaluating niraparib plus dostarlimab vs chemotherapy at physician\'s choice in the treatment of recurrent ovarian, fallopian tube or primary peritoneal cancer patients for which platinum is not an option
Epistemonikos ID: 9ecc0d919b47b07ddd39cb8bc3f0d92d4e84eede
First added on: May 08, 2024